See more : BANDAI NAMCO Holdings Inc. (NCBDY) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaTher Holdings Ltd. (PHRRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaTher Holdings Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Ahresty Corporation (5852.T) Income Statement Analysis – Financial Results
- Greenyard NV (GREEN.BR) Income Statement Analysis – Financial Results
- Asahi Broadcasting Group Holdings Corporation (9405.T) Income Statement Analysis – Financial Results
- BorrowMoney.com, Inc. (BWMY) Income Statement Analysis – Financial Results
- Fasadgruppen Group AB (publ) (FG.ST) Income Statement Analysis – Financial Results
PharmaTher Holdings Ltd. (PHRRF)
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.42K | 1.78K | 355.00 | 0.00 |
| Gross Profit | 0.00 | -1.42K | -1.78K | -355.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.14M | 3.02M | 2.61M | 751.54K | 0.00 |
| General & Administrative | 904.37K | 941.72K | 1.36M | 1.68M | 142.90K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 23.67K |
| SG&A | 904.37K | 941.72K | 1.36M | 1.68M | 23.82K |
| Other Expenses | 0.00 | 24.99K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.04M | 4.01M | 4.10M | 2.82M | 23.82K |
| Cost & Expenses | 3.04M | 4.01M | 4.10M | 2.82M | 23.82K |
| Interest Income | 0.00 | 206.82K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 711.00 | 1.42K | 1.78K | 355.00 | 142.90K |
| EBITDA | -3.04M | -3.96M | -3.96M | -2.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.04M | -1.38M | -3.97M | -8.52M | -23.82K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -71.26K | -2.46M | -274.03K | 5.32M | 0.00 |
| Income Before Tax | -3.12M | -6.42M | -4.24M | 2.89M | -23.82K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.43M | -225.05K | 225.05K | -142.90 |
| Net Income | -3.12M | -6.42M | -4.01M | 2.66M | -23.82K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.07 | -0.05 | 0.04 | 0.00 |
| EPS Diluted | -0.04 | -0.07 | -0.05 | 0.04 | 0.00 |
| Weighted Avg Shares Out | 88.23M | 88.17M | 81.11M | 64.56M | 34.08M |
| Weighted Avg Shares Out (Dil) | 88.23M | 88.17M | 81.11M | 73.26M | 34.08M |
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson's Disease
PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors
PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher's Ketamine Programs
Source: https://incomestatements.info
Category: Stock Reports